Valuation: VolitionRx Limited

Market Cap 3.51M 3.08M 2.89M 2.65M 4.94M 336M 4.98M 34.77M 13.47M 171M 13.17M 12.88M 555M P/E 2026 *
-0.13x
P/E 2027 * -0.25x
Enterprise Value 3.51M 3.08M 2.89M 2.65M 4.94M 336M 4.98M 34.77M 13.47M 171M 13.17M 12.88M 555M EV / Sales 2026 *
1.29x
EV / Sales 2027 * 0.38x
Free-Float
96.42%
Yield 2026 *
-
Yield 2027 * -
1 day-6.16%
1 week-14.62%
Current month-43.07%
1 month-40.75%
3 months-81.57%
6 months-93.40%
Current year-95.17%
1 week 0.23
Extreme 0.2327
0.3
1 month 0.23
Extreme 0.2327
0.72
Current year 0.23
Extreme 0.2327
7.73
1 year 0.23
Extreme 0.2327
14.8
3 years 0.23
Extreme 0.2327
24.6
5 years 0.23
Extreme 0.2327
82.8
10 years 0.23
Extreme 0.2327
136.8
Manager TitleAgeSince
Chief Executive Officer 55 06/10/2011
Director of Finance/CFO 56 01/02/2021
Chief Tech/Sci/R&D Officer 49 01/04/2024
Director TitleAgeSince
Director/Board Member 55 06/10/2011
Director/Board Member 77 06/10/2011
Director/Board Member 64 09/10/2019
Date Insider Type Main position Quantity % Market Cap. Importance
17/3/26
Concord International, Inc.
OtherCompany 0 0% -
17/3/26 Tax

Executive/Senior Manager

5,251 0.0039%
17/3/26 Tax

General Counsel

7,003 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
-6.16%-14.62%-97.99%-98.22% 3.74M
-4.23%+8.87%+380.66%+109.24% 4.82B
-0.61%+4.54%+100.07%+450.10% 4.48B
+1.06%+9.17%+29.15%+95.02% 3.49B
-3.86%+3.17%+262.31%+609.01% 2.92B
+0.48%+21.07%-12.68%-17.58% 2.51B
-4.59%+7.24%+48.11% - 1.77B
-0.58%+5.43%+28.30%+61.14% 1.15B
-1.21%+7.12%+168.00%-23.23% 1.11B
+5.08%+1.02%-13.13%+84.39% 598M
Average -0.93%+5.28%+89.28%+141.10% 2.28B
Weighted average by Cap. -0.48%+8.31%+149.49%+223.15%

Financials

2026 *2027 *
Net sales 2.72M 2.39M 2.25M 2.06M 3.84M 261M 3.87M 27M 10.46M 133M 10.23M 10M 431M 9.27M 8.15M 7.65M 7M 13.07M 888M 13.17M 91.93M 35.62M 453M 34.83M 34.06M 1.47B
Net income -22.25M -19.55M -18.35M -16.8M -31.36M -2.13B -31.61M -221M -85.46M -1.09B -83.55M -81.72M -3.52B -18.42M -16.18M -15.19M -13.91M -25.96M -1.76B -26.16M -183M -70.74M -899M -69.16M -67.64M -2.92B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a company focused on advancing the science of epigenetics. The Company is focused on saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its products are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
57
Date Price Change Volume
23/09/26 USD 0.2470 -6.16% 2,767,976
22/09/26 USD 0.2632 -0.64% 1,717,967
21/09/26 USD 0.2649 +1.88% 1,859,474
18/09/26 USD 0.2600 -8.74% 4,368,077
17/09/26 USD 0.2849 +3.64% 28,229,427
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.2632USD
Average target price
13.62USD
Spread / Average Target
+5,075.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock